Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1619 1638 1654 3783 3786
This examiner grants 19% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18564588 | MRNA DELIVERY USING LIPID NANOPARTICLES | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18710056 | PATCH | Non-Final OA | KANEKA CORPORATION |
| 18284886 | AGENTS FOR DYEING KERATINOUS MATERIAL, IN PARTICULAR HUMAN HAIR, CONTAINING AMINOSILICONES, PIGMENTS AND PARTICULAR ALKYLENE GLYCOLS | Final Rejection | HENKEL AG & CO. KGAA |
| 18576696 | COMPOSITIONS AND METHODS FOR DECREASING PIGMENTATION | Non-Final OA | The General Hospital Corporation |
| 17916115 | MESOPOROUS SILICA NANOPARTICLES, METHODS OF MAKING, AND METHODS OF USING | Non-Final OA | UNM RAINFOREST INNOVATIONS |
| 18678857 | COSMETIC COMPOSITION FOR IMMEDIATELY IMPROVING THE APPEARANCE OF SKIN | Non-Final OA | L'OREAL |
| 18543657 | COMPOSITIONS CONTAINING ACTIVE AGENT AND UV PROTECTION PROPERTIES | Final Rejection | L'OREAL |
| 18479393 | DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | UNIVERSITY OF SOUTH CAROLINA |
| 18706770 | COSMETIC | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18540458 | Synthesis of Thiophene Derivatized Polyphenolic Calixarenes | Final Rejection | University of Cincinnati |
| 18989164 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17925099 | GOLD NANOPARTICLE-CONTAINING MEDICINE | Non-Final OA | OSAKA UNIVERSITY |
| 18844789 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Non-Final OA | Harrow IP, LLC |
| 17774128 | POLYMERIC LINKERS FOR A GASTRIC RESIDENCE SYSTEM | Non-Final OA | Nortiva Bio, Inc. |
| 18392640 | TREATMENT OF DELIRIUM USING NITROUS OXIDE | Final Rejection | Penland Foundation |
| 18513527 | BEVERAGE COMPOSITIONS FOR HYDRATION AND FOR SUPPORT OF HAIR HEALTH | Non-Final OA | CELMATRIX CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy